amyloidosis

AstraZeneca Plc (NASDAQ: AZN) will take complete control of Caelum Biosciences in a deal worth up to $500 million, sharpening its focus on rare-disease drugs following its purchase of Alexion Pharmaceuticals. Caelum was founded by Fortress Biotech Inc (...

Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion and recommended granting marketing authorization to Genmab A/S (NASDAQ: GMAB) and its partner Janssen Biotech Inc's Darzalex (daratumumab) subcutaneous...

Safety and tolerability have been recurrent concerns regarding the drugs produced by Ionis Pharmaceuticals Inc (NASDAQ: IONS), according to Morgan Stanley's David N. Lebowitz, which has kept the stock valuation in check. Lebowitz initiated coverage of the company with an Equal-Weight rating and...